These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 23123579

  • 1. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
    Coin A, Veronese N, Bolzetta F, De Rui M, Manzato E, Sergi G.
    Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579
    [Abstract] [Full Text] [Related]

  • 2. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
    Deane A, Constancio L, Fogelman I, Hampson G.
    BMC Musculoskelet Disord; 2007 Jan 10; 8():3. PubMed ID: 17214897
    [Abstract] [Full Text] [Related]

  • 3. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
    Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, Leung A, Samanta S, Heyden N, McGinnis JP, Rosenberg E, Denker AE.
    Osteoporos Int; 2016 Jan 10; 27(1):377-86. PubMed ID: 26556736
    [Abstract] [Full Text] [Related]

  • 4. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
    Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T.
    J Clin Endocrinol Metab; 2001 Mar 10; 86(3):1212-21. PubMed ID: 11238511
    [Abstract] [Full Text] [Related]

  • 5. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun 10; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 6. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD, Möller G.
    Rheumatol Int; 2009 Dec 10; 30(2):213-21. PubMed ID: 19430791
    [Abstract] [Full Text] [Related]

  • 7. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
    Gorai I, Hattori S, Tanaka Y, Iwaoki Y.
    J Bone Miner Metab; 2012 May 10; 30(3):349-58. PubMed ID: 22130786
    [Abstract] [Full Text] [Related]

  • 8. Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients.
    Giampà E, Di Bonito M, Ferretti V, Nuvoli G, Paoletti F, Piazzini M, Ranieri M, Tuveri MA, Vinicola V.
    Minerva Endocrinol; 2019 Dec 10; 44(4):344-350. PubMed ID: 31971357
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
    Park SY, Kang MI, Park HM, Rhee Y, Moon SH, Yoon HK, Koh JM, Chang JS, Kim IJ, Won YY, Park YS, Choi H, Shin CS, Yoon TR, Yun SC, Chung HY, IDEAL Trial Investigators.
    Arch Osteoporos; 2019 Dec 09; 15(1):3. PubMed ID: 31820121
    [Abstract] [Full Text] [Related]

  • 10. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
    Gao C, Qiao J, Li SS, Yu WJ, He JW, Fu WZ, Zhang ZL.
    Osteoporos Int; 2017 Jan 09; 28(1):211-218. PubMed ID: 27468899
    [Abstract] [Full Text] [Related]

  • 11. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
    Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ.
    J Bone Miner Res; 2004 Aug 09; 19(8):1221-30. PubMed ID: 15231008
    [Abstract] [Full Text] [Related]

  • 12. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
    Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM.
    J Clin Endocrinol Metab; 2006 Apr 09; 91(4):1370-5. PubMed ID: 16449339
    [Abstract] [Full Text] [Related]

  • 13. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 09; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 14. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE.
    Lancet Oncol; 2012 Mar 09; 13(3):275-84. PubMed ID: 22318095
    [Abstract] [Full Text] [Related]

  • 15. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
    Guan YT, Cai LL, Ding HX, Chen GD, Hu Y.
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug 09; 45(8):571-4. PubMed ID: 21029610
    [Abstract] [Full Text] [Related]

  • 16. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
    Panico A, Lupoli GA, Fonderico F, Marciello F, Martinelli A, Assante R, Lupoli G.
    Thyroid; 2009 May 09; 19(5):437-42. PubMed ID: 19415993
    [Abstract] [Full Text] [Related]

  • 17. Increased Serum 25(OH)D3 Levels in Post-Menopausal Japanese Women with Osteoporosis after 3-Year Bisphosphonate Treatment.
    Nakamura Y, Uchiyama S, Kamimura M, Ikegami S, Komatsu M, Kato H.
    Tohoku J Exp Med; 2017 Jul 09; 242(3):241-246. PubMed ID: 28740036
    [Abstract] [Full Text] [Related]

  • 18. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb 09; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 19. Vitamin D status and parathyroid hormone levels in relation to bone mineral density in apparently healthy Syrian adults.
    Sayed-Hassan R, Abazid N, Koudsi A, Alourfi Z.
    Arch Osteoporos; 2016 Feb 09; 11():18. PubMed ID: 27126333
    [Abstract] [Full Text] [Related]

  • 20. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K, Sonoda T, Takada J, Dohke T, Yamashita T.
    J Bone Miner Metab; 2017 Mar 09; 35(2):171-176. PubMed ID: 26832388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.